| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 08/30/2007 | WO2007097361A1 Immunoglobulin affinity ligand |
| 08/30/2007 | WO2007097065A1 Hapten compound and antibody |
| 08/30/2007 | WO2007096536A1 Anti-idiotypic antibody which neutralizes the inhibitory activity of an inhibitory antibody directed against the c1 domain of factor viii |
| 08/30/2007 | WO2007096396A2 Methods for treating autoimmune or demyelinating diseases |
| 08/30/2007 | WO2007096199A2 Differential diagnostics and therapy of virally induced heart muscle disease |
| 08/30/2007 | WO2007096149A1 Thymic stromal lympho po i et in (tslp) antibodies and uses thereof |
| 08/30/2007 | WO2007096142A2 Vascular tumor markers |
| 08/30/2007 | WO2007095749A1 Cytotoxicity mediation of cells evidencing surface expression of trop-2 |
| 08/30/2007 | WO2007095748A1 Cancerous disease modifying antibody 141205-05 |
| 08/30/2007 | WO2007095747A1 Cytotoxicity mediation of cells evidencing surface expression of cd59 |
| 08/30/2007 | WO2007095746A1 Cancerous disease modifying antibodies |
| 08/30/2007 | WO2007095745A1 Cancerous disease modifying antibody 141205-02 |
| 08/30/2007 | WO2007095729A1 Cytotoxicity mediation of cells evidencing surface expression of cd63 |
| 08/30/2007 | WO2007077365A3 IMMUNOGLOBULIN G (IgG) CONCENTRATE DEPLETED OF ANTI-A AND ANTI-B ANTIBODIES AND OF POLYREACTIVE IgGs |
| 08/30/2007 | WO2007056411A3 Method of producing pan-specific antibodies |
| 08/30/2007 | WO2007039818A3 Antigen binding molecules having modified fc regions and altered binding to fc receptors |
| 08/30/2007 | WO2007014278A3 B-cell reduction using cd37-specific and cd20-specific binding molecules |
| 08/30/2007 | WO2005062954A3 Modulation of hcn channels by second messengers |
| 08/30/2007 | US20070203328 Novel hemopoietin receptor protein, NR12 |
| 08/30/2007 | US20070203327 Transcription factor of MHC class II genes, substances capable of inhibiting this transcription factor and medical uses of these substanaces |
| 08/30/2007 | US20070203325 Integrase-dirived HIV-inhibiting agents |
| 08/30/2007 | US20070203070 28 human secreted proteins |
| 08/30/2007 | US20070203057 Compounds and methods for modulating adhesion molecule function |
| 08/30/2007 | US20070202591 Nucleotide sequences coding streptococcal pyrogenic exotoxin A and B proteins for treatment and prevention of food poisoning, bacterial arthritis and autoimmune disorders |
| 08/30/2007 | US20070202575 Asthma; ellergy vaccine; antisense therapy; used to treat, prevent, or ameliorate the symptoms resulting from exposure to a bio-warfare agent |
| 08/30/2007 | US20070202572 Microorganisms for therapy |
| 08/30/2007 | US20070202566 Hydrolases, Nucleic Acids Encoding Them And Methods For Making And Using Them |
| 08/30/2007 | US20070202553 Dominant B Cell Epitopes and Methods of Making and Using Thereof |
| 08/30/2007 | US20070202552 Binding Polypeptides and Uses Thereof |
| 08/30/2007 | US20070202550 Novel G protein-coupled receptor protein, its DNA and ligand thereof |
| 08/30/2007 | US20070202544 Methods For Diagnosing And Treating Endoplasmic Reticulum (er) Stress Diseases |
| 08/30/2007 | US20070202537 Biomarkers for als |
| 08/30/2007 | US20070202528 Methods for modulating proteins not previously known as proteases |
| 08/30/2007 | US20070202524 Targeted Vectors |
| 08/30/2007 | US20070202520 Novel lipase |
| 08/30/2007 | US20070202516 Gene detection assay for improving the likelihood of an effective response to an egfr antagonist cancer therapy |
| 08/30/2007 | US20070202510 Methods for diagnosing and treating kidney cancer |
| 08/30/2007 | US20070202116 Staphylococcal infections using glycopeptide antibiotic eg vancomycin |
| 08/30/2007 | US20070202113 Cell surface glycoprotein specific immunoglobulin for use in prevention and treatment of cell proliferative disorders; antitumor agents |
| 08/30/2007 | US20070202111 Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis |
| 08/30/2007 | US20070202110 Angiogenesis Inhibiting Molecules And Their Use In The Treatment And Diagnosis Of Cancer |
| 08/30/2007 | US20070202108 Antithrombotic agents; monoclonal antibody that inhibits collagen-induced platelet aggregation at an IC50 of less than 7 mu g/ml |
| 08/30/2007 | US20070202105 Recombinant immunoglobulin specific to tumor necrosis factor for treatment and prevention of sepsis, infection and autoimmune diseases |
| 08/30/2007 | US20070202104 Treatment of spondyloarthropathies using TNFalpha inhibitors |
| 08/30/2007 | US20070202103 Compounds For Targeting |
| 08/30/2007 | US20070202102 High-Yield Method For The Production Of Human Antibodies Blocking The Biological Activity Of A Human Cytokine |
| 08/30/2007 | US20070202101 Combination therapy using anti-EGFR antibodies and anti-hormonal agents |
| 08/30/2007 | US20070202100 Using programmed death-1 (PD-1) protein as evaluative tool to identify modulators for treatment and prevention of nervous system, autoimmune, cell proliferative and allergic disorders |
| 08/30/2007 | US20070202099 Antibody Drug |
| 08/30/2007 | US20070202098 Her2/neu OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION |
| 08/30/2007 | US20070202097 Monoclonal Antibodies That Recognise Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1), Soluble Madcam-1 And Uses Thereof |
| 08/30/2007 | US20070202045 Serum albumin binding peptides for tumor targeting |
| 08/30/2007 | US20070202044 Antibody therapy |
| 08/30/2007 | US20070202043 Cell surface glycoprotein specific immunoglobulin for use in prevention and treatment of cell proliferative disorders; antitumor agents |
| 08/30/2007 | US20070202042 Isolated monoclonal antibody produced by hybridoma deposit IDAC accession number 141205-02; customization of therapy for each individual; kits |
| 08/30/2007 | US20070202041 Cancerous disease modifying antibodies |
| 08/30/2007 | CA2643603A1 Cytotoxicity mediation of cells evidencing surface expression of trop-2 |
| 08/30/2007 | CA2643565A1 Anti-idiotypic antibody which neutralizes the inhibitory activity of an inhibitory antibody directed against the c1 domain of factor viii |
| 08/30/2007 | CA2643561A1 Cancerous disease modifying antibody 141205-05 |
| 08/30/2007 | CA2643555A1 Cytotoxicity mediation of cells evidencing surface expression of cd59 |
| 08/30/2007 | CA2643226A1 Antibodies against human il-22 and uses therefor |
| 08/30/2007 | CA2643144A1 Cancerous disease modifying antibody 141205-04 |
| 08/30/2007 | CA2643063A1 Cancerous disease modifying antibody 141205-02 |
| 08/30/2007 | CA2643059A1 Cytotoxicity mediation of cells evidencing surface expression of cd63 |
| 08/30/2007 | CA2638851A1 Thymic stromal lymphopoietin (tslp) antibodies and uses thereof |
| 08/30/2007 | CA2638117A1 Generation of heavy-chain only antibodies in transgenic animals |
| 08/30/2007 | CA2636449A1 Vascular tumor markers |
| 08/30/2007 | CA2635445A1 Methods for treating autoimmune or demyelinating diseases |
| 08/30/2007 | CA2628253A1 Therapeutic anti-her2 antibody fusion polypeptides |
| 08/30/2007 | CA2626100A1 Treatment for antiphospholipid-syndrome-related pregnancy complications |
| 08/29/2007 | EP1826218A1 Antihuman baff antibody |
| 08/29/2007 | EP1825864A2 Antithrombotic agents |
| 08/29/2007 | EP1825005A2 Mer diagnostic and therapeutic agents |
| 08/29/2007 | EP1824987A2 Immunoglobulin variable region cassette exchange |
| 08/29/2007 | EP1824979A2 Methods, products and uses involving platelets and/or the vasculature |
| 08/29/2007 | EP1824978A1 Hcv f protein and uses thereof |
| 08/29/2007 | EP1824887A2 Cytotoxic antibody directed against type b lymphoid hematopoietic proliferations |
| 08/29/2007 | EP1824886A2 Fully human monoclonal antibodies to il-13 |
| 08/29/2007 | EP1824885A1 Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy |
| 08/29/2007 | EP1824884A1 Production of antibody formats and immunological applications of said formats |
| 08/29/2007 | EP1824880A1 Soluble hla-e molecules and their use for diagnosing and treating pathologies |
| 08/29/2007 | EP1824514A2 Toll like receptor 3 antagonists, methods and uses |
| 08/29/2007 | EP1697746A4 Risk markers for cardiovascular disease |
| 08/29/2007 | EP1670903B1 Treatment of neurodegenerative diseases |
| 08/29/2007 | EP1654358A4 Binding constructs and methods for use thereof |
| 08/29/2007 | EP1292710B1 Matrix screening method |
| 08/29/2007 | EP1140997B1 Chlamydia trachomatis antigens |
| 08/29/2007 | EP1054963B1 Sequences of an ih ionic channel and the use thereof |
| 08/29/2007 | EP1047301B1 Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (prrsv) |
| 08/29/2007 | EP0975755B9 Crsp protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor |
| 08/29/2007 | EP0950067B1 Affinity purification of polypeptide on protein a matrix |
| 08/29/2007 | EP0910635B1 Hematopoietic cytokine receptor |
| 08/29/2007 | CN101027391A Methods and compositions for improving recombinant protein production |
| 08/29/2007 | CN101027390A Lrp4/Corin dopamine-producing neuron precursor cell marker |
| 08/29/2007 | CN101027322A 促红细胞生成素受体结合抗体 Erythropoietin receptor antibody |
| 08/29/2007 | CN101027320A FGFR binding peptides |
| 08/29/2007 | CN101027319A 肝素结合肽 Heparin-binding peptides |
| 08/29/2007 | CN101027100A Method for treating sjogren's syndrome |
| 08/29/2007 | CN101027085A Anti-cancer activity of an anti-thymidine kinase monoclonal antibody |
| 08/29/2007 | CN101027084A Mutated HIV NEF for modulating immunity |